About: Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 19 January 2017

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2017 (ast) наукова стаття, опублікована в січні 2017 (uk) مقالة علمية نشرت في 19 يناير 2017 (ar) scientific article published on 19 January 2017 (en)
publication date	wds:Q37593796-97603DC0-10DD-4D3E-B8CE-D99EC404DF56
publication date	2017-01-19 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37593796-2EBB7CFA-EA2B-479B-B51A-033BB4906305
language of work or name	English
exact match	wds:Q37593796-22857B70-CB4B-4D4D-8C9A-318D509DFDAB
exact match	https://scigraph.springernature.com/pub.10.1186/s13045-016-0384-9
cites work	wds:Q37593796-00F1569B-AA6F-4AD6-93EA-3DD10318AFCB wds:Q37593796-02B7A8B0-B597-42CA-8473-15D108019DD9 wds:Q37593796-11C9899F-15B9-43EF-B314-F1F816DC452E wds:Q37593796-2CF47C78-9C18-4728-9564-EC25BA1708E4 wds:Q37593796-3D469300-7984-4BE7-BDB2-272348B8C554 wds:Q37593796-5FD9C340-E073-40D3-B937-2E33B9EF367A wds:Q37593796-60030F0A-EC84-449B-8D0E-9769895DF656 wds:Q37593796-6723883A-3391-4541-998B-69480FA5983A wds:Q37593796-885586D4-AE38-4C49-819D-E5ADBC9DE719 wds:Q37593796-89D46235-D0A2-4827-96AA-E3501F23E907 wds:Q37593796-A7B57A13-5C22-4037-9250-58ED2C08D568 wds:Q37593796-AD7C9723-E283-4D73-838C-0DE613B74AE6 wds:Q37593796-B2913E63-5FA7-46BA-98AF-0602299B294C wds:Q37593796-B8D8852A-DE73-4D5D-A315-16B97F9B645D wds:Q37593796-D664AF77-D337-47E0-9E0A-483C8A7FDAA7 wds:Q37593796-DE3F0407-8C51-4477-9DDD-941001C66355 wds:Q37593796-E2E83C76-DFF4-4303-8B98-1D77F1654F5F wds:Q37593796-E78F7BA8-13E9-4730-842D-0A428A716E63
cites work	Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab Metastatic colorectal cancer: current state and future directions Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Molecular mechanisms and clinical applications of angiogenesis Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Ramucirumab, another anti-angiogenic agent for metastatic colorectal cancer in second-line setting--its impact on clinical practice Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial Pharmacogenomics of intrinsic and acquired pharmacoresistance in colorectal cancer: Toward targeted personalized therapy. Antiangiogenic therapy in oncology: current status and future directions A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Advances in targeted and immunobased therapies for colorectal cancer in the genomic era Clinical outcomes of Chinese patients with metastatic colorectal cancer receiving first-line bevacizumab-containing treatment. Colorectal cancer: Overcoming resistance to anti-EGFR therapy - where do we stand?
author name string	wds:Q37593796-0F531BC8-0FA6-4AC0-A772-00E525A875EA wds:Q37593796-48B62475-B07B-4EA2-AB28-E7A92B12391A wds:Q37593796-4DFF40BF-C756-4447-809D-E70D2556CDD6 wds:Q37593796-64BA4D58-CDC6-4238-8F3E-30A05A7E8EED wds:Q37593796-69F679D1-C584-482E-B5A3-B8B1F3863525 wds:Q37593796-6BFCBBCC-27A8-4AC0-8B6D-C54D2127B4A8 wds:Q37593796-7AB6DECD-CEF1-4190-8292-2A1E839A96D3 wds:Q37593796-8604205B-471A-432F-AAF0-000677CEC177 wds:Q37593796-88C87B88-96F6-466C-954D-3E8244EF8515 wds:Q37593796-A64F00D0-194A-4108-B3DB-92AD39EFCCA5 wds:Q37593796-CE82C723-92D0-4402-9CDD-CAE0ADABE4C4 wds:Q37593796-D316E77D-F90E-4160-9C6F-52FDD04B25AB wds:Q37593796-DCB47E39-6FA7-42A4-9EF1-3183901856B7
author name string	Jin Li Lin Shen Liwei Wang Jianming Xu Dongsheng Zhang Hongming Pan Yuxian Bai Rui-Hua Xu Tianshu Liu Junning Cao Ye Hua Songhua Fan Weiguo Su
rdfs:label	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study (en) Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study (ast) Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. (nl)
skos:prefLabel	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study (en) Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study (ast) Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. (nl)
name	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study (en) Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study (ast) Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. (nl)
title	wds:Q37593796-77D049AB-392F-4334-81AE-6A7B25BDC0F2
title	Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study (en)
page(s)	wds:Q37593796-BED51CF4-A6D4-4963-A3E1-5665296C4090
page(s)	22
instance of	wds:Q37593796-8319EA6E-FC92-4E08-AB48-EEC605967630
instance of	scholarly article

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 183 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software